Altimmune Inc (3G0 F) stock market data APIs
€3.0054
0(0%)
as of December 30, 2025
Try our APIs with
free plan!
Altimmune Inc Financial Data Overview
Price chart is built with
Anychart
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Prev. Close
3.0054
Open
3.0054
High
3.0054
Low
3.0054
52 wk Range
2.32-7.366
Market Cap
315 M
Shares Outstanding
104 M
Revenue
20 000
EPS
-0.53
Beta
-0.036
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Altimmune Inc data using free add-ons & libraries
Get Altimmune Inc Fundamental Data
Altimmune Inc Fundamental data includes:
- Net Revenue: 20 000
- EBITDA: -90 343 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.32
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Altimmune Inc News
New
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
Altimmune, Inc GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract on pemvidutide in subjects w...
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Altimmune, Inc Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end of treatment Over 30% of subjects achieved 20% or more weight loss o...
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
Altimmune, Inc Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) ...
Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
Altimmune, Inc GAITHERSBURG, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 20...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
